ADIPOQ and chronic kidney disease: This effect may or may not be beneficial as described by Guo et al., 2009, and may be due to alterations in kidney function (e.g. clearance of adiponection) and/or the development of adiponectin resistance in CKD (and subsequent reversal following ARB administration) [124].